Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant.

Cancer research - 1 Aug 1994

Mineta T, Rabkin S D, Martuza R L

Abstract excerpt

We have demonstrated that attenuated mutants of herpes simplex virus (HSV) have therapeutic potential for malignant brain tumors. In this report, we tested a ribonucleotide reductase-deficient (RR-) HSV mutant as an experimental treatment for malignant brain tumors. The HSV-RR- mutant hrR3, containing an Escherichia coli lacZ gene insertion in the ICP6 gene that encodes the large subunit of RR, was used in this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Drug Resistance
Share to Mice

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mice, Inbred BALB C

Share to Mice, Nude

Share to Mutation

Share to Tumor Cells, Cultured

Share to Vero Cells

Source

Identifiers

PMID: 8033122

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant.PMID 8033122Read ↗

Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase.Semantic proximity Read ↗

Therapeutic Efficiency and Safety of a Second-Generation Replication-Conditional HSV1 Vector for Brain Tumor Gene TherapySemantic proximity Read ↗

Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir.Semantic proximity Read ↗

Toxicity and neuronal infection of a HSV-1 ICP34.5 mutant in nude mice.Semantic proximity Read ↗

Evaluation of the antitumor effects of Herpes simplex virus lacking ribonucleotide reductase in a murine retinoblastoma model.Semantic proximity Read ↗

Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice.Semantic proximity Read ↗

An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy.Semantic proximity Read ↗

Mutant herpes simplex virus induced regression of tumors growing in immunocompetent rats.Semantic proximity Read ↗

Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours - evaluation of a potentially effective clinical therapySemantic proximity Read ↗

A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors.Semantic proximity Read ↗

Mutant herpes simplex virus-mediated suppression of retinoblastoma.Semantic proximity Read ↗

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.